 Allergan Inc Chief Executive David Pyott is looking at potential sizable acquisitions at the urging of his shareholders he said on Wednesday as he seeks to fight off a  billion hostile offer from Valeant Pharmaceuticals International Inc and activist investor William Ackman Mr Pyott in an interview said he was always looking at potential targets and pointed to an estimated  billion in future freecash flow and his companys ability to easily raise a hefty amount of debt as giving him the firepower for a deal